News
OCX
0.4250
-3.41%
-0.0150
Exact Sciences Up 25% YTD: Here Is What To Expect In 2023
Seeking Alpha · 01/11 21:13
Why Graphite Bio Shares Are Trading Lower By 50%; Here Are 20 Stocks Moving Premarket
Benzinga · 01/06 13:00
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 12/28/2022 21:32
GlycoMimetics And 3 Other Stocks Under $3 Insiders Are Aggressively Buying
Benzinga · 12/28/2022 16:11
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 12/26/2022 17:32
OncoCyte's Return On Capital Employed Insights
Benzinga · 12/21/2022 14:47
Precision Diagnostics Company Oncocyte Cuts 40% Of Its Workforce
Benzinga · 12/16/2022 14:56
BRIEF-OncoCyte Announces Reduction Of Workforce Over 40%
Reuters · 12/16/2022 13:39
Oncocyte Cuts 40% Of Staff -- MarketWatch
Market Watch · 12/16/2022 13:20
Oncocyte cuts 40% of staff
Marketwatch.com · 12/16/2022 13:19
Oncocyte Announces 40% Workforce Reduction; Co. To Also Enter Stock Purchase Agreement To Transfer 70% Of Ownership In Razor Genomics
Benzinga · 12/16/2022 13:06
Oncocyte Announces Initiatives to Focus Corporate Strategy
IRVINE, Calif., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced a reduction in force involving over 40% of Oncocyte’s workforce to realign its team towards key products that address lar...
GlobeNewswire · 12/16/2022 13:00
Oncocyte to Reduce Workforce More Than 40%, Sell 70% Stake in Razor Genomics
Oncocyte to Reduce Workforce More Than 40%, Sell 70% Stake in Razor Genomics
MT Newswires · 12/16/2022 09:33
--Street Color: OncoCyte Intends to Reduce Workforce by More Than 40%
--Street Color: OncoCyte Intends to Reduce Workforce by More Than 40%
MT Newswires · 12/16/2022 08:36
Analyst Ratings for OncoCyte
Benzinga · 12/01/2022 20:01
Expert Ratings for OncoCyte
Benzinga · 12/01/2022 18:03
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2022
Benzinga · 12/01/2022 15:01
Lake Street Downgrades OncoCyte to Hold, Lowers Price Target to $0.5
Benzinga · 12/01/2022 14:13
--Lake Street Downgrades Oncocyte to Hold From Buy, Cuts Price Target to $0.50 From $3
--Lake Street Downgrades Oncocyte to Hold From Buy, Cuts Price Target to $0.50 From $3
MT Newswires · 12/01/2022 10:38
OncoCyte's Chief Executive Ronnie Andrews Steps Down
OncoCyte's Chief Executive Ronnie Andrews Steps Down
MT Newswires · 12/01/2022 03:30
More
Webull provides a variety of real-time OCX stock news. You can receive the latest news about Oncocyte Corporation through multiple platforms. This information may help you make smarter investment decisions.
About OCX
OncoCyte Corporation is a molecular diagnostics company. The Company is focused on developing and commercializing proprietary tests, initially offered as laboratory-developed tests (LDTs), to serve unmet medical needs across the cancer care continuum. The Company’s products include DetermaRx, DetermaIO, and DetermaCNI. DetermaRx is a commercialized predictive molecular test for early-stage adenocarcinoma of the lung. This gene expression-based test provides information that a physician can use to identify early-stage, surgically resected patients with Stage I and IIA non-squamous non-small cell lung cancer (NSCLC). DetermaIO is developed to identify patients to respond to immunotherapy drugs. Its predictive biomarkers, including PD-L1 and Tumor Mutational Burden to predict, which patients responds to immunotherapy. DetermaCNI is a tumor-informed tests that are on market for treatment monitoring as well as blood-only targeted panels.